Myocardial Infarction incidence during national lockdown in two French provinces unevenly affected by COVID-19 outbreak: An observational study.
COVID-19 outbreak
COVID-19, Coronavirus disease 2019
Clinical outcome
MI, Myocardial Infarction
Mortality
Myocardial Infarction
NSTEMI, non ST-segment elevation myocardial infarction
STEMI, ST-segment elevation myocardial infarction
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
entrez:
26
6
2021
pubmed:
27
6
2021
medline:
27
6
2021
Statut:
ppublish
Résumé
A reduction of admission for MI has been reported in most countries affected by COVID-19. No clear explanation has been provided. To report the incidence of myocardial infarction (MI) admission during COVID-19 pandemic and in particular during national lockdown in two unequally affected French provinces (10-million inhabitants) with a different media strategy, and to describe the magnitude of MI incidence changes relative to the incidence of COVID-19-related deaths. A longitudinal study to collect all MIs from January 1 until May 17, 2020 (study period) and from the identical time period in 2019 (control period) was conducted in all centers with PCI-facilities in northern "Hauts-de-France" province and western "Pays-de-la-Loire" Province. The incidence of COVID-19 fatalities was also collected. In "Hauts-de-France", during lockdown (March 18-May 10), 1500 COVID-19-related deaths were observed. A 23% decrease in MI-IR (IRR=0.77;95%CI:0.71-0.84, It highlights one of the potential collateral damages of COVID-19 outbreak on cardiovascular health with a dramatic reduction of MI incidence. It advocates for a careful and weighted communication strategy in pandemic crises. The study was conducted without external funding.
Sections du résumé
BACKGROUND
BACKGROUND
A reduction of admission for MI has been reported in most countries affected by COVID-19. No clear explanation has been provided.
METHODS
METHODS
To report the incidence of myocardial infarction (MI) admission during COVID-19 pandemic and in particular during national lockdown in two unequally affected French provinces (10-million inhabitants) with a different media strategy, and to describe the magnitude of MI incidence changes relative to the incidence of COVID-19-related deaths. A longitudinal study to collect all MIs from January 1 until May 17, 2020 (study period) and from the identical time period in 2019 (control period) was conducted in all centers with PCI-facilities in northern "Hauts-de-France" province and western "Pays-de-la-Loire" Province. The incidence of COVID-19 fatalities was also collected.
FINDINGS
RESULTS
In "Hauts-de-France", during lockdown (March 18-May 10), 1500 COVID-19-related deaths were observed. A 23% decrease in MI-IR (IRR=0.77;95%CI:0.71-0.84,
INTERPRETATION
CONCLUSIONS
It highlights one of the potential collateral damages of COVID-19 outbreak on cardiovascular health with a dramatic reduction of MI incidence. It advocates for a careful and weighted communication strategy in pandemic crises.
FUNDING
BACKGROUND
The study was conducted without external funding.
Identifiants
pubmed: 34173627
doi: 10.1016/j.lanepe.2021.100030
pii: S2666-7762(21)00007-7
pmc: PMC7938895
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100030Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Dr. Lemesle reports personal fees from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Lilly, MSD, Mylan, Novartis, Novonordisk, Pfizer, Sanofi Aventis, Servier, outside the submitted work. Dr Delhaye reports personal fees from Medtronic outside the submitted work. Dr. Cayla reports personal fees from Amgen, personal fees from Astra Zeneca, personal fees from Bayer, personal fees from Biotronik, personal fees from Bristol Myers Squibb, grants and personal fees from Medtronic, personal fees from MSD, personal fees from Pfizer, personal fees from Sanofi, outside the submitted work. The other authors do not report any conflict of interest.
Références
N Engl J Med. 2020 Jul 2;383(1):88-89
pubmed: 32343497
Eur Heart J. 2020 May 14;41(19):1852-1853
pubmed: 32297932
JACC Case Rep. 2020 Aug;2(10):1651-1653
pubmed: 32839761
Eur Heart J Qual Care Clin Outcomes. 2020 Jul 1;6(3):223-224
pubmed: 32348457
N Engl J Med. 2020 Aug 13;383(7):691-693
pubmed: 32427432
Acta Med Scand. 1957 Dec 12;159(4):253-74
pubmed: 13508095
Circ Cardiovasc Interv. 2020 Jul;13(7):e009438
pubmed: 32600109
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872
pubmed: 32283124
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111
Catheter Cardiovasc Interv. 2020 Aug 7;:
pubmed: 32767652
J Am Coll Cardiol. 2020 Nov 17;76(20):2321-2330
pubmed: 33183506
Lancet Public Health. 2020 Oct;5(10):e536-e542
pubmed: 32950075
Clin Res Cardiol. 2020 Dec;109(12):1577-1578
pubmed: 32533248